Clinical trial
Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their…
NCT00352053 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00352053 |
|---|---|
| Title | Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy |
| Official title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Tenofovir DF as Part of an Optimized Antiretroviral Regimen in HIV-1-Infected Adolescents |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Tenofovir DF, Placebo |
| Enrollment | 87 |
| Start date | Jun 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Dec 1, 2013 |
| First posted | Jul 14, 2006 |
| Last update posted | Jul 14, 2015 |
| Countries | Brazil, Panama |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: